Bannerbild German Brest Group - Studien

GeparOcto (GBG 84)

GeparOcto

A randomised phase III trial to compare two dose-dense, dose-intensified therapy approaches (ETC and PM (Cb)) for the neoadjuvant treatment of high-risk patients primary breast cancer.

 
 

News

Status: Trial in Follow-Up

Design

This is a multi-centre, prospective, randomised, open-label phase III trial with two different dose-dense, dose-intensified approaches to neoadjuvant therapy for patients with untreated high-risk, early-stage breast cancer.

Patients will be randomised to one of the following two arms:

ETC arm:

  • Epirubicin 150 mg/m² every 2 weeks for 3 cycles, followed by
  • Paclitaxel 225 mg/m² every 2 weeks for 3 cycles, followed by
  • Cyclophosphamide 2000 mg/m² every 2 weeks for 3 cycles.

or
PM(Cb) arm:

  • Paclitaxel 80 mg/m² 18 times a week, administered concurrently with
  • NPLD (Myocet®) 20 mg/m² 18 times a week, administered concurrently with
  • Carboplatin AUC 1.5 18 times a week (only for patients with triple-negative breast cancer).

Further information for participating sites can be found in the password-protected section of this website for internal use.

Documents

The most important documents relating to the GeparOcto trial can be downloaded here.

Berechtigte und angemeldete Benutzer können hier weitere interne Dokumente abrufen. Haben Sie bereits einen Login? Dann melden Sie sich hier an.

Contact

gprctgrmnbrstgrpd
Fax: +4961027480440

Project Manager
Konstantin Reißmüller
Tel: +4961027480438
knstntnrssmllrgbgd

Monitoring
Udo Pfeil
Tel.: +4961027480421
dpflgbgd

Contact

gprctgbgd
Fax: +4961027480440

Project management
Konstantin Reißmüller

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd